相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings
Horst-Dieter Hummel et al.
IMMUNOTHERAPY (2021)
Preclinical Assessment of AMG 596, a Bispecific T-cell Engager (BiTE) Immunotherapy Targeting the Tumor-specific Antigen EGFRvIII
Alexander Sternjak et al.
MOLECULAR CANCER THERAPEUTICS (2021)
A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Divya Mathur et al.
CLINICAL CANCER RESEARCH (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
Characterization of a Novel FLT3 BITE Molecule for the Treatment of Acute Myeloid Leukemia
Bettina Brauchle et al.
MOLECULAR CANCER THERAPEUTICS (2020)
AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys
Rebecca L. Goldstein et al.
BLOOD ADVANCES (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Taking a BiTE out of ALL: blinatumomab approval for MRD-positive ALL
Emily Curran et al.
BLOOD (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE (R)) antibody construct, in patients with refractory solid tumors
Maxim Kebenko et al.
ONCOIMMUNOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro
Ling Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability
Frederick W. Jacobsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Recent advances of bispecific antibodies in solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer
Jos P. M. van Putten et al.
JOURNAL OF INNATE IMMUNITY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Phase Ia and lb studies of the novel carcinoembryonic antigen (CEA) 1-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
Harnessing T cells to fight cancer with BiTE® antibody constructs - past developments and future directions
Matthias Klinger et al.
IMMUNOLOGICAL REVIEWS (2016)
Discovery and bio-optimization of human antibody therapeutics using the XenoMouse® transgenic mouse platform
Ian N. Foltz et al.
IMMUNOLOGICAL REVIEWS (2016)
Cell line with endogenous EGFRvIII expression is a suitable model for research and drug development purposes
Wojciech J. Stec et al.
ONCOTARGET (2016)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110
Wibke Deisting et al.
PLOS ONE (2015)
Alterations of the apical junctional complex and actin cytoskeleton and their role in colorectal cancer progression
Adriana Sartorio Gehren et al.
TISSUE BARRIERS (2015)
CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas
Michael D. Oberst et al.
MABS (2014)
The Genotype-Tissue Expression (GTEx) project
John Lonsdale et al.
NATURE GENETICS (2013)
Interpreting Stress Responses during Routine Toxicity Studies: A Review of the Biology, Impact, and Assessment
Nancy E. Everds et al.
TOXICOLOGIC PATHOLOGY (2013)
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
Dhaval K. Shah et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2012)
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Jordi Barretina et al.
NATURE (2012)
Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment
Danila Coradini et al.
ACTA PHARMACOLOGICA SINICA (2011)
Transmembrane mucins as novel therapeutic targets
Pamela E. Constantinou et al.
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2011)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
Aya Jakobovits et al.
NATURE BIOTECHNOLOGY (2007)
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration
Eva-Maria Krinner et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Human discs large and scrib are localized at the same regions in colon mucosa and changes in their expression patterns are correlated with loss of tissue architecture during malignant progression
Daniela Gardiol et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3
P Laidler et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2005)
Mucins in cancer: Protection and control of the cell surface
MA Hollingsworth et al.
NATURE REVIEWS CANCER (2004)
分享论文
